Top

Current HIV/AIDS Reports

Published in:

01-06-2018 | Complications of Antiretroviral Therapy (GA McComsey, Section Editor)

Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update

Author: Todd Hulgan

Published in: Current HIV/AIDS Reports | Issue 3/2018

Abstract

Purpose of Review

This narrative review summarizes recent data on factors associated with insulin resistance (IR) in adults with HIV, including contemporary antiretroviral therapy (ART).

Recent Findings

IR remains common in persons with HIV, even those receiving contemporary ART. Generalized and abdominal obesity and ectopic fat are correlates of IR, and emerging data have identified associations with biomarkers of inflammation and immune activation. Small studies suggest associations between mitochondria and IR. In ART-naïve individuals, IR increased within 4 weeks of starting ART in persons receiving contemporary boosted protease inhibitors or an integrase inhibitor.

Summary

The importance of IR in non-diabetic persons with HIV will continue to grow as the population ages and obesity increases. Non-invasive estimates of IR appear to perform well in persons with HIV, but clinically relevant cutoffs are uncertain. Unexpected metabolic effects of newer HIV integrase inhibitors have been reported; thus, careful observation for and studies of IR are still warranted.

Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354(9184):1112–5.PubMedCrossRef

Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med. 1990;322(16):1098–105.PubMedCrossRef

Finkle HI. Hepatic mitochondrial toxicity from nucleoside analog therapy. Arch Pathol Lab Med. 1999;123(3):189.PubMed

Le Bras P, D'Oiron R, Quertainmont Y, Halfon P, Caquet R. Metabolic, hepatic and muscular changes during zidovudine therapy: a drug-induced mitochondrial disease? AIDS. 1994;8(5):716–7.PubMedCrossRef

Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs. 2003;63(23):2555–74.PubMedCrossRef

Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351(9119):1881–3. https://doi.org/10.1016/s0140-6736(98)03391-1.PubMedCrossRef

Gan SK, Samaras K, Carr A, Chisholm D. Anti-retroviral therapy, insulin resistance and lipodystrophy. Diabetes Obes Metab. 2001;3(2):67–71.PubMedCrossRef

Nolan D, Mallal S. Getting to the HAART of insulin resistance. AIDS. 2001;15(15):2037–41.PubMedCrossRef

Lake JE, Currier JS. Metabolic disease in HIV infection. Lancet Infect Dis. 2013;13(11):964–75. https://doi.org/10.1016/s1473-3099(13)70271-8.PubMedCrossRef

10.

Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. Diabetes Care. 2007;30(2):318–24. https://doi.org/10.2337/dc06-0919.PubMedCrossRef

11.

•• Brener MI, Post WS, Haberlen SA, Zhang L, Palella FJ Jr, Jacobson LP, et al. Comparison of insulin resistance to coronary atherosclerosis in human immunodeficiency virus infected and uninfected men (from the multicenter AIDS cohort study). Am J Cardiol. 2016;117(6):993–1000. https://doi.org/10.1016/j.amjcard.2015.12.037. Important analysis of IR in MACS affirms higher HOMA-IR in men with HIV than those without, and associations between HOMA-IR and coronary stenosis.PubMedCrossRef

12.

Valcour V, Rubin LH, Tien P, Anastos K, Young M, Mack W, et al. Human immunodeficiency virus (HIV) modulates the associations between insulin resistance and cognition in the current combination antiretroviral therapy (cART) era: a study of the Women’s Interagency HIV Study (WIHS). J Neuro-Oncol. 2015;21(4):415–21. https://doi.org/10.1007/s13365-015-0330-6.CrossRef

13.

• Non LR, Escota GV, Powderly WG. HIV and its relationship to insulin resistance and lipid abnormalities. Transl Res. 2017;183:41–56. https://doi.org/10.1016/j.trsl.2016.12.007. Thorough current review covering epidemiology, pathogenesis, and evidence for direct HIV effects on IR; an extensive bibliography.PubMedCrossRef

14.

• Willig AL, Overton ET. Metabolic Complications and Glucose metabolism in HIV infection: a review of the evidence. Curr HIV/AIDS Rep. 2016;13(5):289–96. https://doi.org/10.1007/s11904-016-0330-z. Another current review; succinct, accessible, and clinically relevant.PubMedPubMedCentralCrossRef

15.

Soumaya K. Molecular mechanisms of insulin resistance in diabetes. Adv Exp Med Biol. 2012;771:240–51.PubMed

16.

Yazici D, Sezer H. Insulin resistance, obesity and lipotoxicity. Adv Exp Med Biol. 2017;960:277–304. https://doi.org/10.1007/978-3-319-48382-5_12.PubMedCrossRef

17.

Feeney ER, Mallon PW. Insulin resistance in treated HIV infection. Best Pract Res Clin Endocrinol Metab. 2011;25(3):443–58. https://doi.org/10.1016/j.beem.2010.11.002.PubMedCrossRef

18.

Blazquez D, Ramos-Amador JT, Sainz T, Mellado MJ, Garcia-Ascaso M, De Jose MI, et al. Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults. BMC Infect Dis. 2015;15:119. https://doi.org/10.1186/s12879-015-0853-8.PubMedPubMedCentralCrossRef

19.

Dejkhamron P, Unachak K, Aurpibul L, Sirisanthana V. Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy. J Pediatr Endocrinol Metab. 2014;27(5–6):403–12. https://doi.org/10.1515/jpem-2013-0253. PubMedCrossRef

20.

Hazra R, Hance LF, Monteiro JP, Ruz NP, Machado DM, Saavedra M, et al. Insulin resistance and glucose and lipid concentrations in a cohort of perinatally HIV-infected Latin American children. Pediatr Infect Dis J. 2013;32(7):757–9. https://doi.org/10.1097/INF.0b013e318286c774.PubMedPubMedCentralCrossRef

21.

Innes S, Abdullah KL, Haubrich R, Cotton MF, Browne SH. High prevalence of dyslipidemia and insulin resistance in HIV-infected prepubertal African children on antiretroviral therapy. Pediatr Infect Dis J. 2016;35(1):e1–7. https://doi.org/10.1097/inf.0000000000000927.PubMedPubMedCentralCrossRef

22.

Sharma TS, Jacobson DL, Anderson L, Gerschenson M, Van Dyke RB, McFarland EJ, et al. Short communication: the relationship between mitochondrial dysfunction and insulin resistance in HIV-infected children receiving antiretroviral therapy. AIDS Res Hum Retrovir. 2013;29(9):1211–7. https://doi.org/10.1089/aid.2012.0354. PubMedPubMedCentralCrossRef

23.

Takemoto JK, Miller TL, Wang J, Jacobson DL, Geffner ME, Van Dyke RB, et al. Insulin resistance in HIV-infected youth is associated with decreased mitochondrial respiration. AIDS. 2017;31(1):15–23. https://doi.org/10.1097/qad.0000000000001299.PubMedCrossRef

24.

Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015;75(10):1071–94. https://doi.org/10.1007/s40265-015-0416-8.PubMedPubMedCentralCrossRef

25.

DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Phys. 1979;237(3):E214–23. https://doi.org/10.1152/ajpendo.1979.237.3.E214.CrossRef

26.

Otten J, Ahren B, Olsson T. Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis. Diabetologia. 2014;57(9):1781–8. https://doi.org/10.1007/s00125-014-3285-x.PubMedCrossRef

27.

Hommes MJ, Romijn JA, Endert E, Eeftinck Schattenkerk JK, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism. 1991;40(6):651–6.PubMedCrossRef

28.

Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr. 2000;25(4):312–21.PubMedCrossRef

29.

Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001;15(7):F11–8.PubMedPubMedCentralCrossRef

30.

van der Valk M, Bisschop PH, Romijn JA, Ackermans MT, Lange JM, Endert E, et al. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS. 2001;15(16):2093–100.PubMedCrossRef

31.

Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, Brathwaite CE, et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr. 2002;31(2):163–70.PubMedCrossRef

32.

Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, Grunfeld C, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab. 2001;86(8):3480–7. https://doi.org/10.1210/jcem.86.8.7785.PubMedCrossRef

33.

Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002;16(5):F1–8.PubMedPubMedCentralCrossRef

34.

Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23(1):57–63.PubMedCrossRef

35.

Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402–10. https://doi.org/10.1210/jcem.85.7.6661.PubMedCrossRef

36.

Randell PA, Jackson AG, Boffito M, Back DJ, Tjia JF, Taylor J, et al. Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. Antivir Ther. 2010;15(8):1125–32. https://doi.org/10.3851/imp1675.PubMedCrossRef

37.

Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes. 2003;52(4):918–25.PubMedCrossRef

38.

Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–70.PubMedCrossRef

39.

Kim SR, Lerman LO. Diagnostic imaging in the management of patients with metabolic syndrome. Transl Res. 2017;194:1–18. https://doi.org/10.1016/j.trsl.2017.10.009. PubMedCrossRef

40.

Ng JM, Bertoldo A, Minhas DS, Helbling NL, Coen PM, Price JC, et al. Dynamic PET imaging reveals heterogeneity of skeletal muscle insulin resistance. J Clin Endocrinol Metab. 2014;99(1):E102–E6. https://doi.org/10.1210/jc.2013-2095.PubMedCrossRef

41.

Johansson E, Lubberink M, Heurling K, Eriksson JW, Skrtic S, Ahlström H, et al. Whole-body imaging of tissue-specific insulin sensitivity and body composition by using an integrated PET/MR system: a feasibility study. Radiology. 2018;286(1):271–8. https://doi.org/10.1148/radiol.2017162949.PubMedCrossRef

42.

Cade WT, Reeds DN, Overton ET, Herrero P, Waggoner AD, Laciny E, et al. Pilot study of pioglitazone and exercise training effects on basal myocardial substrate metabolism and left ventricular function in HIV-positive individuals with metabolic complications. HIV Clin Trials. 2013;14(6):303–12. https://doi.org/10.1310/hct1406-303.PubMedPubMedCentralCrossRef

43.

Ghotb A, Noworolski SM, Madden E, Scherzer R, Qayyum A, Pannell J, et al. Adipose tissue and metabolic factors associated with steatosis in HIV/HCV coinfection: histology versus magnetic resonance spectroscopy. J Acquir Immune Defic Syndr. 2010;55(2):228–31. https://doi.org/10.1097/QAI.0b013e3181e1d963.PubMedPubMedCentralCrossRef

44.

Price JC, Dodge JL, Ma Y, Scherzer R, Korn N, Tillinghast K, et al. Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults. AIDS. 2017;31(15):2119–25. https://doi.org/10.1097/qad.0000000000001601.PubMedCrossRefPubMedCentral

45.

Sathekge M, Maes A, Kgomo M, Stolz A, Ankrah A, Van de Wiele C. Evaluation of glucose uptake by skeletal muscle tissue and subcutaneous fat in HIV-infected patients with and without lipodystrophy using FDG-PET. Nucl Med Commun. 2010;31(4):311–4. https://doi.org/10.1097/MNM.0b013e3283359058.PubMedCrossRef

46.

Torriani M, Zanni MV, Fitch K, Stavrou E, Bredella MA, Lim R, et al. Increased FDG uptake in association with reduced extremity fat in HIV patients. Antivir Ther. 2013;18(2):243–8. https://doi.org/10.3851/imp2420. PubMedCrossRef

47.

Ioannou GN, Bryson CL, Boyko EJ. Prevalence and trends of insulin resistance, impaired fasting glucose, and diabetes. J Diabetes Complicat. 2007;21(6):363–70. https://doi.org/10.1016/j.jdiacomp.2006.07.005.PubMedCrossRef

48.

Araujo S, Banon S, Machuca I, Moreno A, Perez-Elias MJ, Casado JL. Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs. Eur J Endocrinol. 2014;171(5):545–54. https://doi.org/10.1530/eje-14-0337.PubMedCrossRef

49.

Schulte-Hermann K, Schalk H, Haider B, Hutterer J, Gmeinhart B, Pichler K, et al. Impaired lipid profile and insulin resistance in a cohort of Austrian HIV patients. J Infect Chemother. 2016;22(4):248–53. https://doi.org/10.1016/j.jiac.2016.01.007.PubMedCrossRef

50.

•• Nansseu JR, Bigna JJ, Kaze AD, Noubiap JJ. Incidence and risk factors for prediabetes and diabetes mellitus among HIV infected adults on antiretroviral therapy: systematic review and meta-analysis. Epidemiology. 2018. https://doi.org/10.1097/EDE.0000000000000815. Extensive review of incidence and risk factors; very detailed supplemental tables of individual study results are valuable resource.

51.

• McMahon CN, Petoumenos K, Hesse K, Carr A, Cooper DA, Samaras K. High rates of incident diabetes and prediabetes are evident in men with treated HIV followed for 11 years. AIDS. 2018;32(4):451–9. https://doi.org/10.1097/QAD.0000000000001709. Small study, but longest known follow-up of a single cohort with OGTT capturing transitions to pre-diabetes and diabetes.PubMedCrossRef

52.

• Koethe JR. Adipose tissue in HIV infection. Compr Physiol. 2017;7(4):1339–57. https://doi.org/10.1002/cphy.c160028. Exhaustive review of biological relevance of adipose tissue in metabolic complications of HIV infection and treatment.PubMedCrossRefPubMedCentral

53.

Koethe JR, Hulgan T, Niswender K. Adipose tissue and immune function: a review of evidence relevant to HIV infection. J Infect Dis. 2013;208(8):1194–201. https://doi.org/10.1093/infdis/jit324.PubMedPubMedCentralCrossRef

54.

Lake JE. The fat of the matter: obesity and visceral adiposity in treated HIV infection. Curr HIV/AIDS Rep. 2017;14(6):211–9. https://doi.org/10.1007/s11904-017-0368-6.PubMedCrossRef

55.

Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol. 2014;34(6):1155–61. https://doi.org/10.1161/atvbaha.114.303034.PubMedCrossRef

56.

Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014;371(12):1131–41. https://doi.org/10.1056/NEJMra1011035.PubMedCrossRef

57.

• Longenecker CT, Margevicius S, Liu Y, Schluchter MD, Yun CH, Bezerra HG, et al. Effect of pericardial fat volume and density on markers of insulin resistance and inflammation in patients with human immunodeficiency virus infection. Am J Cardiol. 2017;120(8):1427–33. https://doi.org/10.1016/j.amjcard.2017.07.019. Longitudinal analysis demonstrating independent associations between pericardial fat measured by computed tomography and HOMA-IR in persons with HIV.PubMedCrossRefPubMedCentral

58.

Kaji H. Adipose tissue-derived plasminogen activator Inhibitor-1 function and regulation. Compr Physiol. 2016;6(4):1873–96. https://doi.org/10.1002/cphy.c160004.PubMedCrossRef

59.

Wirunsawanya K, Belyea L, Shikuma C, Watanabe RM, Kohorn L, Shiramizu B, et al. Plasminogen activator Inhibitor-1 predicts negative alterations in whole-body insulin sensitivity in chronic HIV infection. AIDS Res Hum Retrovir. 2017;33(7):723–7. https://doi.org/10.1089/aid.2016.0292.PubMedCrossRef

60.

Shikuma CM, Chow DC, Gangcuangco LM, Zhang G, Keating SM, Norris PJ, et al. Monocytes expand with immune dysregulation and is associated with insulin resistance in older individuals with chronic HIV. PLoS One. 2014;9(2):e90330. https://doi.org/10.1371/journal.pone.0090330.PubMedPubMedCentralCrossRef

61.

Hessol NA, Ameli N, Cohen MH, Urwin S, Weber KM, Tien PC. The association between diet and physical activity on insulin resistance in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr. 2013;62(1):74–80. https://doi.org/10.1097/QAI.0b013e318275d6a4.PubMedPubMedCentralCrossRef

62.

Monroe AK, Brown TT, Cox C, Reynolds SM, Wiley DJ, Palella FJ, et al. Physical activity and its association with insulin resistance in multicenter AIDS cohort study men. AIDS Res Hum Retrovir. 2015;31(12):1250–6. https://doi.org/10.1089/aid.2015.0027.PubMedPubMedCentralCrossRef

63.

Casula M, Mozzanica F, Scotti L, Tragni E, Pirillo A, Corrao G, et al. Statin use and risk of new-onset diabetes: a meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2017;27(5):396–406. https://doi.org/10.1016/j.numecd.2017.03.001.PubMedCrossRef

64.

Muscogiuri G, Sarno G, Gastaldelli A, Savastano S, Ascione A, Colao A, et al. The good and bad effects of statins on insulin sensitivity and secretion. Endocr Res. 2014;39(4):137–43. https://doi.org/10.3109/07435800.2014.952018.PubMedCrossRef

65.

Erlandson KM, Jiang Y, Debanne SM, McComsey GA. Rosuvastatin worsens insulin resistance in HIV-infected adults on antiretroviral therapy. Clin Infect Dis. 2015;61(10):1566–72. https://doi.org/10.1093/cid/civ554.PubMedPubMedCentralCrossRef

66.

Krishnan S, Wilson EM, Sheikh V, Rupert A, Mendoza D, Yang J, et al. Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis. 2014;209(6):931–9. https://doi.org/10.1093/infdis/jit581.PubMedCrossRef

67.

Hunt PW, Lee SA, Siedner MJ. Immunologic biomarkers, morbidity, and mortality in treated HIV infection. J Infect Dis. 2016;214(Suppl 2):S44–50. https://doi.org/10.1093/infdis/jiw275.PubMedPubMedCentralCrossRef

68.

Sell H, Habich C, Eckel J. Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol. 2012;8(12):709–16. https://doi.org/10.1038/nrendo.2012.114.PubMedCrossRef

69.

Koethe JR, Grome H, Jenkins CA, Kalams SA, Sterling TR. The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy. AIDS. 2016;30(1):83–91. https://doi.org/10.1097/QAD.0000000000000893. PubMedPubMedCentralCrossRef

70.

Srinivasa S, Fitch KV, Wong K, Torriani M, Mayhew C, Stanley T, et al. RAAS activation is associated with visceral adiposity and insulin resistance among HIV-infected patients. J Clin Endocrinol Metab. 2015;100(8):2873–82. https://doi.org/10.1210/jc.2015-1461.PubMedPubMedCentralCrossRef

71.

Tincati C, Douek DC, Marchetti G. Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection. AIDS Res Ther. 2016;13:19. https://doi.org/10.1186/s12981-016-0103-1.PubMedPubMedCentralCrossRef

72.

Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 2013;21(1):6–13. https://doi.org/10.1016/j.tim.2012.09.001.PubMedCrossRef

73.

O'Malley TK, Burdo TH, Robinson JA, Fitch KV, Grinspoon SK, Srinivasa S. Acute hyperinsulinemia effects on systemic markers of immune activation in HIV. AIDS. 2017;31(12):1771–3. https://doi.org/10.1097/QAD.0000000000001545.PubMedCrossRefPubMedCentral

74.

Pedersen KK, Pedersen M, Troseid M, Gaardbo JC, Lund TT, Thomsen C, et al. Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance, and risk of myocardial infarction. J Acquir Immune Defic Syndr. 2013;64(5):425–33. https://doi.org/10.1097/QAI.0b013e31829f919d.PubMedCrossRef

75.

Moreno-Perez O, Giner L, Reus S, Boix V, Alfayate R, Frances R, et al. Impact of circulating bacterial DNA in long-term glucose homeostasis in non-diabetic patients with HIV infection: cohort study. Eur J Clin Microbiol Infect Dis. 2018;37(2):313–8. https://doi.org/10.1007/s10096-017-3134-1.PubMedCrossRef

76.

Brown AE, Walker M. Genetics of insulin resistance and the metabolic syndrome. Curr Cardiol Rep. 2016;18(8):75. https://doi.org/10.1007/s11886-016-0755-4.PubMedPubMedCentralCrossRef

77.

Jimenez-Sousa MA, Berenguer J, Fernandez-Rodriguez A, Micheloud D, Guzman-Fulgencio M, Miralles P, et al. IL28RA polymorphism (rs10903035) is associated with insulin resistance in HIV/HCV-coinfected patients. J Viral Hepat. 2014;21(3):189–97. https://doi.org/10.1111/jvh.12130.PubMedCrossRef

78.

Pineda-Tenor D, Berenguer J, Jimenez-Sousa MA, Garcia-Alvarez M, Aldamiz-Echevarria T, Carrero A, et al. FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients. BMC Med. 2014;12:198. https://doi.org/10.1186/s12916-014-0198-y.PubMedPubMedCentralCrossRef

79.

Gonzalez-Franquesa A, Patti ME. Insulin resistance and mitochondrial dysfunction. Adv Exp Med Biol. 2017;982:465–520. https://doi.org/10.1007/978-3-319-55330-6_25. PubMedCrossRef

80.

Wang CH, Wei YH. Role of mitochondrial dysfunction and dysregulation of Ca(2+) homeostasis in the pathophysiology of insulin resistance and type 2 diabetes. J Biomed Sci. 2017;24(1):70. https://doi.org/10.1186/s12929-017-0375-3.PubMedPubMedCentralCrossRef

81.

Shikuma CM, Day LJ, Gerschenson M. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction. Curr Drug Targets Infect Disord. 2005;5(3):255–62.PubMedCrossRef

82.

Hart AB, Samuels DC, Hulgan T. The other genome: a systematic review of studies of mitochondrial DNA haplogroups and outcomes of HIV infection and antiretroviral therapy. AIDS Rev. 2013;15(4):213–20.PubMedPubMedCentral

83.

Micheloud D, Berenguer J, Guzman-Fulgencio M, Campos Y, Garcia-Alvarez M, Catalan P, et al. European mitochondrial DNA haplogroups and metabolic disorders in HIV/HCV coinfected patients on highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2011;58:371–8. https://doi.org/10.1097/QAI.0b013e31822d2629.PubMedCrossRef

84.

Hulgan T, Stein JH, Cotter BR, Murdock DG, Ritchie MD, Dube MP, et al. Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retrovir. 2013;29(10):1293–9. https://doi.org/10.1089/aid.2013.0079.PubMedPubMedCentralCrossRef

85.

Hulgan T, Ramsey B, Koethe JR, Samuels DC, Gerschenson M, Libutti D et al. Adipose mitochondrial function, adiponectin, and insulin resistance in ACTG A5224S. Conference on Retroviruses and Opportunistic Infections; February 13–16; Boston, MA, USA; 2017.

86.

Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23(9):1109–18. https://doi.org/10.1097/QAD.0b013e32832b4377.PubMedPubMedCentralCrossRef

87.

McComsey GA, Daar ES, O'Riordan M, Collier AC, Kosmiski L, Santana JL, et al. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. J Infect Dis. 2013;207(4):604–11. https://doi.org/10.1093/infdis/jis720.PubMedCrossRef

88.

McComsey GA, Kitch D, Sax PE, Tebas P, Tierney C, Jahed NC, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG study A5224s. Clin Infect Dis. 2011;53(2):185–96. https://doi.org/10.1093/cid/cir324.PubMedPubMedCentralCrossRef

89.

Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Melbourne KM, et al. Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS. 2014;28(10):1451–61. https://doi.org/10.1097/QAD.0000000000000266.PubMedPubMedCentralCrossRef

90.

Ryom L, Lundgren J, El-Sadr WM, Reiss P, Phillips A, Kirk O et al. Association between cardiovascular disease & contemporarily used protease inhibitors. Conference on Retroviruses and Opportunistic Infections; February 13–16; Boston, MA, USA; 2017.

91.

• Lundgren J, Mocroft A, Ryom L. Contemporary protease inhibitors and cardiovascular risk. Curr Opin Infect Dis. 2018;31(1):8–13. https://doi.org/10.1097/QCO.0000000000000425. Important review of evidence for associations between newer PI, including atazanavir and darunavir, and cardiovascular effects.PubMedCrossRef

92.

Overton ET, Tebas P, Coate B, Ryan R, Perniciaro A, Dayaram YK, et al. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial. HIV Clin Trials. 2016;17(2):72–7. https://doi.org/10.1080/15284336.2016.1141468.PubMedPubMedCentralCrossRef

93.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed 3 Feb 2018.

94.

Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796–806. https://doi.org/10.1016/s0140-6736(09)60918-1.PubMedCrossRef

95.

DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379(9835):2429–38. https://doi.org/10.1016/s0140-6736(12)60918-0.PubMedCrossRef

96.

Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835):2439–48. https://doi.org/10.1016/s0140-6736(12)60917-9.PubMedCrossRef

97.

Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735–43. https://doi.org/10.1016/s0140-6736(12)61853-4.PubMedCrossRef

98.

Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–18. https://doi.org/10.1056/NEJMoa1215541.PubMedCrossRef

99.

McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dube MP, et al. Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. Clin Infect Dis. 2016;62(7):853–62. https://doi.org/10.1093/cid/ciw017.PubMedPubMedCentralCrossRef

100.

•• Dirajlal-Fargo S, Moser C, Brown TT, Kelesidis T, Dube MP, Stein JH, et al. Changes in insulin resistance after initiation of raltegravir or protease inhibitors with tenofovir-emtricitabine: AIDS Clinical Trials Group A5260s. Open Forum Infect Dis. 2016;3(3):ofw174. https://doi.org/10.1093/ofid/ofw174. Unique targeted analysis of HOMA-IR in a clinical trial of contemporary ART regimens in treatment-naïve persons; HOMA-IR increased rapidly after starting either boosted PI or RAL-containing ART.PubMedPubMedCentralCrossRef

101.

Zanni MV, Burdo TH, Makimura H, Williams KC, Grinspoon SK. Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin Endocrinol. 2012;77(3):385–90. https://doi.org/10.1111/j.1365-2265.2011.04284.x.CrossRef

102.

Fong PS, Flynn DM, Evans CD, Korthuis PT. Integrase strand transfer inhibitor-associated diabetes mellitus: a case report. Int J STD AIDS. 2017;28(6):626–8. https://doi.org/10.1177/0956462416675107.PubMedCrossRef

103.

Spinner CD, Kern KE, Zink A, Wolf E, Balogh A, Noe S, et al. Neither boosted elvitegravir nor darunavir with emtricitabine/tenofovir disoproxil fumarate increase insulin resistance in healthy volunteers: results from the STRIBILD-IR study. Antivir Ther. 2016;21(7):627–31. https://doi.org/10.3851/imp3049.PubMedCrossRef

104.

Raffi F, Esser S, Nunnari G, Perez-Valero I, Waters L. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. HIV Med. 2016;17(Suppl 5):3–16. https://doi.org/10.1111/hiv.12440. PubMedCrossRef

105.

Menard A, Meddeb L, Tissot-Dupont H, Ravaux I, Dhiver C, Mokhtari S, et al. Dolutegravir and weight gain: an unexpected bothering side effect? AIDS. 2017;31(10):1499–500. https://doi.org/10.1097/QAD.0000000000001495.PubMedCrossRef

106.

Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, et al. Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76(5):527–31. https://doi.org/10.1097/QAI.0000000000001525.PubMedCrossRef

107.

McLaughlin M, Walsh S, Galvin S. Dolutegravir-induced hyperglycaemia in a patient living with HIV. J Antimicrob Chemother. 2018;73(1):258–60. https://doi.org/10.1093/jac/dkx365.PubMedCrossRef

108.

Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354–62. https://doi.org/10.1093/infdis/jiu051.PubMedPubMedCentralCrossRef

109.

Dolutegravir (Tivicay) [Package Insert]. Research Triangle Park, NC, USA: ViiV Healthcare, 2017. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tivicay/pdf/TIVICAY-PI-PIL.PDF. Accessed 6 Feb 2018.

110.

Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. The Lancet HIV. 2017;4(4):e154–e60. https://doi.org/10.1016/S2352-3018(17)30016-4.PubMedCrossRef

111.

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063–72. https://doi.org/10.1016/S0140-6736(17)32299-7.PubMedCrossRef

112.

Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink H-J, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073–82. https://doi.org/10.1016/S0140-6736(17)32340-1.PubMedCrossRef

113.

Minami R, Yamamoto M, Takahama S, Ando H, Miyamura T, Suematsu E. Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir. J Infect Chemother. 2011;17(2):183–8. https://doi.org/10.1007/s10156-010-0101-5.PubMedCrossRef

114.

Moure R, Domingo P, Gallego-Escuredo JM, Villarroya J, Gutierrez Mdel M, Mateo MG, et al. Impact of elvitegravir on human adipocytes: alterations in differentiation, gene expression and release of adipokines and cytokines. Antivir Res. 2016;132:59–65. https://doi.org/10.1016/j.antiviral.2016.05.013.PubMedCrossRef

115.

Perez-Matute P, Perez-Martinez L, Blanco JR, Oteo JA. Neutral actions of raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes. Curr HIV Res. 2011;9(3):174–9.PubMedCrossRef

116.

Masich A, Badowski ME, Liedtke MD, Fulco PP. Evaluation of the concurrent use of dolutegravir and metformin in human immunodeficiency virus-infected patients. Int J STD AIDS. 2017;28(12):1229–33. https://doi.org/10.1177/0956462417695995.PubMedCrossRef

117.

Song IH, Zong J, Borland J, Jerva F, Wynne B, Zamek-Gliszczynski MJ, et al. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic Syndr. 2016;72(4):400–7. https://doi.org/10.1097/qai.0000000000000983.PubMedPubMedCentralCrossRef

Title: Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update
Author: Todd Hulgan
Publication date: 01-06-2018
Publisher: Springer US
Published in: Current HIV/AIDS Reports / Issue 3/2018
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-018-0399-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2018

Network Research Experiences in New York and Eastern Europe: Lessons for the Southern US in Understanding HIV Transmission Dynamics

HIV and Cardiovascular Disease: Update on Clinical Events, Special Populations, and Novel Biomarkers

Syringe Decriminalization Advocacy in Red States: Lessons from the North Carolina Harm Reduction Coalition

NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?

Integrated Models of Care for Individuals with Opioid Use Disorder: How Do We Prevent HIV and HCV?

Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page